KR20150036538A - Application of gynura divaricata in preparing medicine or health food for treating hepatitis - Google Patents

Application of gynura divaricata in preparing medicine or health food for treating hepatitis Download PDF

Info

Publication number
KR20150036538A
KR20150036538A KR1020157003623A KR20157003623A KR20150036538A KR 20150036538 A KR20150036538 A KR 20150036538A KR 1020157003623 A KR1020157003623 A KR 1020157003623A KR 20157003623 A KR20157003623 A KR 20157003623A KR 20150036538 A KR20150036538 A KR 20150036538A
Authority
KR
South Korea
Prior art keywords
extract
water
white
hours
alcohol
Prior art date
Application number
KR1020157003623A
Other languages
Korean (ko)
Inventor
웨이콴 리
주안 통
동샤오 리
Original Assignee
웨이콴 리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 웨이콴 리 filed Critical 웨이콴 리
Publication of KR20150036538A publication Critical patent/KR20150036538A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

백자채를 간염 치료 약물 또는 건강식품 제조에 응용한 것으로, 백자채 알코올 추출물의 고용량 그룹은 사염화탄소로 인한 작은 쥐의 급성 간 손상을 뚜렷이 억제할 수 있으며, 글루타민산 피루빈산 트랜스아미나제(GPT) 및 글루타민산 옥살로초산 트랜스아미나제(GOT)를 강하시키고, 간세포 변성과 괴사를 경감시킬 수 있다.The high-dose group of white tea alcohols extracts can significantly inhibit the acute liver damage of small rats caused by carbon tetrachloride, and the glutamate pyruvate transaminase (GPT) and It is possible to lower the glutamate oxaloacetic acid transaminase (GOT) and alleviate liver cell degeneration and necrosis.

Description

백자채(GYNURA DIVARICATA)의 간염 치료 약물 또는 건강식품 제조에의 응용{APPLICATION OF GYNURA DIVARICATA IN PREPARING MEDICINE OR HEALTH FOOD FOR TREATING HEPATITIS}BACKGROUND OF THE INVENTION 1. Field of the Invention [0001] The present invention relates to a method for preparing a medicament for the treatment of hepatitis of GYNURA DIVARICATA (GYNURA DIVARICATA)

본 발명은 중약 분야에 관한 것으로서, 특히 중약 단방인 백자채의 제약 및 건강식품에 있어서의 용도에 관한 것이다.Field of the Invention The present invention relates to the field of Chinese medicine, and more particularly to the use of white tea beans in Chinese medicine as a single ingredient for pharmaceuticals and health foods.

백자채(白子菜)는 또한 백배삼칠(白背三七)이라고도 하며, 국화과 식물 백자채 Gynura divaricata(L.) DC. [G. oualis DC. G.pseudo-china(L.) DC.]의 전초이다. 백자채의 별명은 대비우(大肥牛)(《광주식물지》), 토생지(土生地), 백자채약(白仔菜藥), 산혈강(散血姜)(《광서약식도지》), 토전칠(土田七)(《광서중약지》), 창도약(槍刀藥), 청심채(淸心菜), 백혈피채(白血皮菜), 호두칠(胡豆七), 대운병약(大暈病藥), 대만선초(台灣仙草), 익수신초(益壽神草), 생명수(生命樹), 용선초(龍仙草), 신초(神草) 등이다. 백자채는 여러해살이풀로, 높이는 30-60cm이고 줄기는 직립이거나 기부(基部)가 다소간 위쪽으로 기울어지고, 목질이며, 건조 시 골이 지고, 가지가 갈라지지 않거나 또는 상부에 화서 가지가 있는 경우도 있으며, 털이 없거나 또는 짧고 부드러운 털이 덮여있고, 약간 보라색을 띤다. 잎이 두껍고 통상적으로 하부에 집중되어 있으며, 잎꼭지가 있거나 또는 거의 꼭지가 없다. 잎은 계란형, 타원형 또는 도피침형이며, 길이는 2-15cm, 폭은 1.5-5cm이고, 상단은 뭉툭하거나 또는 급격히 뾰족해지는 형태이며, 기부는 쐐기형으로 좁거나 또는 아래로 잎자루가 연장되고, 거의 절두형 또는 약간 하트 모양이며, 가장자리에 톱니가 있고, 수금 형상으로 균열되는 경우가 있으며, 가장자리가 완전한 경우가 드물다. 상면은 녹색이고, 하면은 보라색을 띠며, 측맥은 3-5쌍이고, 세맥은 흔히 거의 평행한 긴 원형의 미세 망으로 연결되며, 건조 시 선명한 검은 선이 나타나고, 양면은 짧고 부드러운 털로 덮여있다. 잎자루의 길이는 0.5-4cm이고, 짧고 부드러운 털이 있으며, 기부는 계란형 또는 반월형으로 톱니를 갖는 귀가 있다. 상부의 잎은 점차로 작아지며, 포엽상이고, 좁은 피침형 또는 선형이며, 깃털 형상으로 옅은 균열이 있고 자루가 없으며 줄기가 약간 감싸져 있다. 두상 화서의 직경은 1.5-2cm이고, 통상적으로 (2) 3-5개가 줄기 또는 가지 끝에 성긴 산방 형상의 원뿔형 화서가 배열되고, 포크 형상으로 가지가 갈라져 있다. 꽃자루 길이는 1-15cm이고, 부드러운 털이 조밀하게 덮여 있으며, 1-3개의 선형 포엽을 갖는다. 총포는 종 형상이고, 길이는 8-10mm, 폭은 6-8mm이며, 기부에 다수의 선형 또는 실 모양의 작은 꽃받침이 있다. 총포는 1겹으로 11-14개이며, 좁은 피침형이고, 길이는 8-10mm, 폭 1-2mm이며, 상단이 점차 뾰족해져 긴 삼각형을 이루면서 가장자리는 건피질이고, 배면에 3개의 맥을 가지며, 성기고 짧은 털이 덮여있거나 또는 거의 털이 없다. 낱꽃은 오렌지색으로 향기가 있으며, 총포에서 약간 뻗어 나와 있다. 화관의 길이는11-15mm이고, 관부가 가늘며, 길이는 9-11mm로 상부가 확대되어 벌어진 잎은 긴 원 형상의 계란형이고, 상단은 적색으로 뾰족하다. 꽃밥의 기부는 뭉툭하거나 또는 창끝 모양이며; 화주의 분지가 가늘고, 원추형 부속지가 있으며, 유두형 털이 덮여있다. 수과는 원주형으로, 길이는 약 5mm이며, 갈색이고, 10줄의 골이 있으며, 미세한 털이 덮여있고; 관모는 백색이고, 비단털 형상이며, 길이는 10-12mm이다. 결실기는 8-10월이다. 약재 및 탕약의 성상은 뿌리 줄기 덩어리로, 가늘고 긴 수염뿌리가 있다. 줄기는 원기둥형이고, 갈자색이며, 짧은 털이 덮여 있고, 잎이 번갈아 나며, 주름이 많고, 완전한 잎은 긴 계란형 내지 긴 원형의 거꾸로 된 계란형이며, 길이는 5-15cm, 폭 2.5-8cm이고, 선단은 뭉뚝하거나 또는 짧고 뾰족하고, 기부는 2개의 귀가 있는 경우가 있으며, 잎의 가장자리에 불규칙한 홈과 톱니가 있고, 상하면은 모두 부드러운 털이 있다. 때때로 두상화서 또는 총포를 볼 수 있다. 수과(瘦果)는 진한 갈색이고, 관모는 백색이다. 기가 약하고, 맛이 옅다. 백자채는 광동(광주, 남해), 해남(징매, 애현, 만녕, 보정, 경중, 경산 등), 홍콩, 운남(경동, 홍하, 녹춘)에 분포되어 있으며, 베트남 북부에도 분포되어 있다. 청열량혈, 활혈지통, 지혈의 효과가 있으며, 해소, 기관지염, 폐결핵, 창양, 부종통, 탕상, 타박상, 류머티즘, 자궁출혈, 외상출혈에 사용된다. 백일해, 골절, 창상출혈, 용종창절을 치료한다. 백자채에는 n-에이코산(n-Eicosane), 테트라코사놀(Tetracosanol), 옥타코사놀산(Octacosanoic acid), 옥타코실알코올(Octacosyl alcohol), 팔미트산(Palmitic acid), 스티그마스테롤-3-O-β-D-글루코피라노사이드(Stigmasterol-3-O-β-D-glucopyranoside), 스티그마스테롤(Stigmasterol), β-시토스테롤(β-Sitosterol), 다우코스테롤(Daucosterol), 프리델린(Friedelin) 등 성분을 함유한다. 현대 연구에서 일정한 혈당강하 작용이 있음이 밝혀졌다.White potato (白子 菜) is also called Baekdang Samchechil (白 背 三七), and asteraceae white porcelain Gynura divaricata (L.) DC. [ G. oualis DC. G. pseudo-china (L.) DC.]. The nickname of white porcelain is the name of the potato ("Gwangju Flora"), the soil of the land, the white porcelain (白 仔 菜 药), the red blood gang (" (刀 刀), 刀 刀 (刀 刀 药), 淸 心 菜, 白血 皮菜, walnut 七 七 (胡豆 七), a great illness红 仙草, and Shingo are the most common species in the world. White porcelain is a perennial plant with a height of 30-60cm and its stem is upright or base is slightly inclined upwards and is woody. When dried, it becomes prone, branches do not split, It is either hairless or covered with short, soft hairs and slightly purple. The leaves are thick and usually concentrated in the lower part, with or without faucets. Leaves are oval, elliptical or obovate type, 2-15cm long, 1.5-5cm wide, with a stumpy or sharp pointed top, basal wedge-like or narrow petiole extending It is a double or slightly heart-shaped, with sawteeth at the edges, cracks in the shape of a lollipop, and rarely complete edges. The upper surface is green, the lower surface is purple, the side veins are 3-5 pairs, and the veins are often connected by a nearly circular long fine mesh, with a sharp black line appearing on drying, and both sides covered with short, soft fur. The petiole is 0.5-4cm long, has short, soft hairs, and the base is egg-shaped or moon-shaped with ears with teeth. The upper leaf is gradually smaller, bract lobed, narrow lanceolate or linear, feathery, with a slight crack, no bark, and a small stem wrapped around it. The diameter of the epididymis is 1.5-2 cm, and usually (2) three to five stems or a conical flower-shaped conical flower shape are arranged at the end of the branch, and the branch is divided into a fork shape. The length of the peduncle is 1-15cm, it is densely covered with soft hairs, and has 1-3 linear bracts. The involucre is a bell-shaped, 8-10 mm long, 6-8 mm wide, and has numerous linear or thread-shaped calyxes at the base. The involucre is 11-14 in one layer, narrow lanceolate, 8-10mm long, 1-2mm wide, with the top gradually becoming acute and forming a long triangle, the edge is the dry cortex and the back has three veins , Short, or almost hairless. The flower is orange-scented, and extends slightly from the gun. The length of the corolla is 11-15mm, the tube is thin, the length is 9-11mm, the upper part is enlarged and the leaf is long oval egg shape, and the top is pointed red. The base of the anther is blunt or lanceolate; Shrub branch is thin, conical appendix, covered with papillary hair. Achenia is columnar, about 5mm long, brown, with 10 rows of bracts, covered with fine hairs; The hairs are white, silky, and 10-12mm long. The fertility period is 8-10 months. Medicinal properties of medicinal plants and herbal medicines are rootstock, with thin and long hairs. The stem has a cylindrical shape, a dark purple color, short hairs covered, alternate leaves and wrinkles, and a complete leaf is an inverted oval shape of long egg-shaped to long circular shape, 5-15 cm long, 2.5-8 cm wide, The tip is blunt or short and pointed. The base has two ears. The edge of the leaf has irregular grooves and serrations. The upper and lower sides have soft hairs. Occasionally you can see headstands or guns. Achenes are dark brown with white hairs. It is weak and the taste is pale. The white porcelain is distributed in Guangdong (Gwangju, Namhae), Haenam (Jungmae, Ayeon, Mangyeong, Baekje, Jungjung, Gyeongsan), Hongkong, Yunnan (Kyungdong, Hongha and Nokchun) and also in northern Vietnam. It is used for bleeding, bronchitis, pulmonary tuberculosis, swallowing, edema, swelling, bruising, rheumatism, uterine bleeding, trauma hemorrhage. Whooping cough, fractures, bleeding wounds, and swelling of the dragon. White porcelain contains n-eicosane, tetracosanol, octacosanoic acid, octacosyl alcohol, palmitic acid, stigmasterol-3-O- Stigmasterol, 3-O-β-D-glucopyranoside, Stigmasterol, β-Sitosterol, Daucosterol, Friedelin, etc. ≪ / RTI > Modern research has shown that there is a certain blood glucose lowering effect.

본 발명의 목적은 간장을 효과적으로 보호할 수 있는 백자채의 일종의 신규한 용도를 제공하고자 하는데 있다.It is an object of the present invention to provide a kind of novel use of white pigments capable of effectively protecting the liver.

본 발명의 목적은 다음과 같이 실현된다: 백자채의 간염 치료 약물 또는 건강식품 제조에의 응용에 있어서, 상기 약물 또는 건강식품은 백자체 추출물과 통상적인 용량의 약제학적으로 허용 가능한 보조재를 혼합하여 제조되는 임상적으로 허용 가능한 제제이다.The object of the present invention is realized as follows: In the treatment of hepatitis in white porcelain, in the application to the manufacture of medicaments or health food products, the medicaments or health foods are prepared by mixing a bagasse extract with a conventional amount of a pharmaceutically acceptable auxiliary material Is a clinically acceptable formulation to be manufactured.

상기 백자채 추출물은 물 추출물 또는 알코올 추출물이다.The white raspberry extract is a water extract or an alcohol extract.

상기 물 추출물의 제조방법은 백자채에 8~12배의 물을 첨가하고, 1.5~2시간동안 달인 후, 찌꺼기에 다시 5~8배량의 물을 첨가하여 1~1.5시간 동안 달여 추출액을 합병한 후 여과 농축시키는 단계를 포함한다.The water extract is prepared by adding 8 to 12 times of water to white flour, stirring for 1.5 to 2 hours, adding 5 to 8 times of water to the residue, adding the extract for 1 to 1.5 hours Followed by filtration.

상기 알코올 추출물의 제조방법은 백자채에 8~12배의 75%~90% 에탄올을 첨가하고, 1.5~2시간 동안 환류 추출한 후, 찌꺼기에 75%~90%배량의 물을 첨가하여 1~1.5시간 동안 달여 추출액을 합병한 후 여과하고, 에탄올을 회수하여 농축시키는 단계를 포함한다.The alcohol extract is prepared by adding 75% to 90% of ethanol to 8 to 12 times of white flour, refluxing for 1.5 to 2 hours, adding 75 to 90% of water to the residue, For a period of time, combining the extract with the filtrate, and recovering and concentrating the ethanol.

상기 제제는 임상적으로 허용 가능한 과립제, 캡슐제, 정제 또는 구복액이다.The formulation is a pharmaceutically acceptable granule, capsule, tablet or fabric solution.

본 발명은 연구를 거쳐 CCl4로 인한 작은 쥐의 급성 간 손상에 대하여, 백자채 알코올 추출, 물 추출물의 고용량 그룹에서 뚜렷한 억제 작용이 있음을 발견하였으며, 혈청 글루타민산 피루빈산 트랜스아미나제(GPT) 및 글루타민산 옥살로초산 트랜스아미나제(GOT)를 하강시켜, 간세포 변성과 괴사를 경감시키는 것으로 나타났다.The present invention has been found to have a significant inhibitory effect on the acute liver injury caused by CCl 4 in a high dose group of white algae extract and water extract, and the serum glutamate pyruvate transaminase (GPT) , And glutamate oxaloacetic acid transaminase (GOT) to lower hepatocyte denaturation and necrosis.

이하는 본 발명의 약간의 구체적인 실시예로서, 본 발명을 더 구체적으로 설명하기 위한 것이나, 단 본 발명은 이러한 실시에로만 한정되지 않는다.DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present invention will be described in more detail with reference to some specific embodiments of the present invention, but the present invention is not limited to these embodiments.

실시예Example 1(물 추출) 1 (water extraction)

백자채에 8배의 물을 첨가하여 추출하며, 1차에 2시간 동안 추출하고, 2차에 8배량의 물을 첨가하여 1.5시간 동안 추출한 다음, 추출액을 합병한 후 여과, 농축, 건조시켜 갈색 분말상을 수득한다. 추출물의 수득률(마지막 분말 수득률을 투입된 약재 중량으로 나눈)은 6~10%이다.The extract was extracted by adding 8 times water to white porcelain and extracted for 2 hours in the first step and 8 times in water for the second time. After extracting for 1.5 hours, the extract was combined, filtered, concentrated and dried to obtain brown A powder phase is obtained. The yield of the extract (the final powder yield divided by the weight of the injected drug) is 6-10%.

실시예Example 2(물 추출) 2 (water extraction)

백자채에 10배의 물을 첨가하여 추출하며, 1차에 1.5시간 동안 추출하고, 2차에 6배량의 물을 첨가하여 1.2시간 동안 추출한 다음, 추출액을 합병한 후 여과, 농축, 건조시켜 갈색 분말상을 수득한다. 추출물의 수득률은 6~10%이다.The white liquor was extracted by adding 10 times of water. The extract was extracted for 1.5 hours in the first step, 6 times in water was added for the second time, and the extract was extracted for 1.2 hours. After the extract was combined with the filtrate, A powder phase is obtained. The yield of the extract is 6-10%.

실시예Example 3(물 추출) 3 (water extraction)

백자채에 12배의 물을 첨가하여 추출하며, 1차에 1.5시간 동안 추출하고, 2차에 5배량의 물을 첨가하여 1시간 동안 추출한 다음, 추출액을 합병한 후 여과, 농축, 건조시켜 갈색 분말상을 수득한다. 추출물의 수득률은 6~10%이다.The extract was extracted by adding 12 times water to white porcelain and extracted for 1.5 hours in the first step and 5 times in water in the second time. The extract was then extracted for 1 hour. After the extract was combined with the filtrate, A powder phase is obtained. The yield of the extract is 6-10%.

실시예Example 4(알코올 추출) 4 (Alcohol Extraction)

백자채에 10배의 80% 알코올을 첨가하고, 2시간 동안 환류 추출한 다음, 찌꺼기에 다시 80% 배량의 물을 첨가하여 1.5시간 동안 달이고, 추출액을 합병하여 여과하고, 에탄올을 회수하여, 농축, 건조시켜 갈색 분말상을 수득한다. 추출물의 수득률은 6~8%이다.80% alcohol was added to white porcelain, and the mixture was refluxed for 2 hours. Then, 80% by volume of water was added to the residue, and the mixture was allowed to stand for 1.5 hours. The extract was combined, filtered and ethanol was recovered, And dried to obtain a brown powdery phase. The yield of the extract is 6-8%.

실시예Example 5(알코올 추출) 5 (Alcohol Extraction)

백자채에 8배의 90% 알코올을 첨가하고, 1.5시간 동안 환류 추출한 다음, 찌꺼기에 다시 90% 배량의 물을 첨가하여 1시간 동안 달이고, 추출액을 합병하여 여과하고, 에탄올을 회수하여, 농축, 건조시켜 갈색 분말상을 수득한다. 추출물의 수득률은 6~8%이다.90% alcohol was added to white porcelain, and the mixture was refluxed for 1.5 hours. Then, 90% by volume of water was added to the residue, and the mixture was stirred for 1 hour. The extract was combined, filtered and ethanol was recovered, And dried to obtain a brown powdery phase. The yield of the extract is 6-8%.

실시예Example 6(알코올 추출) 6 (Alcohol Extraction)

백자채에 12배의 75% 알코올을 첨가하고, 2시간 동안 환류 추출한 다음, 찌꺼기에 다시 75% 배량의 물을 첨가하여 1.5시간 동안 달이고, 추출액을 합병하여 여과하고, 에탄올을 회수하여, 농축, 건조시켜 갈색 분말상을 수득한다. 추출물의 수득률은 6~8%이다.Twelve times 75% alcohol was added to white porcelain, refluxed for 2 hours, 75% of water was added to the residue, and the mixture was allowed to stand for 1.5 hours. The extract was combined, filtered and ethanol was recovered, And dried to obtain a brown powdery phase. The yield of the extract is 6-8%.

실시예Example 7(과립제) 7 (granule)

처방: 중량부에 따라, 실시예 1로 얻은 물 추출물 1부, 수크로오스 2.5부, 덱스트린 1.5부로 계산한다.Prescription: Calculate with 1 part of the water extract obtained in Example 1, 2.5 parts of sucrose and 1.5 parts of dextrin, depending on the weight part.

제조방법: 추출물 분말을 수크로오스와 덱스트린에 첨가하고 고르게 혼합하여 과립으로 제조한 후, 건조시켜 분리 포장한다.Preparation method: Extract powder is added to sucrose and dextrin and mixed well to prepare granules, which are then dried and separated.

성상: 본 제품은 황갈색의 과립이며, 맛이 약간 달고 쓰다.Appearance: This product is a yellowish brown granule, taste a little sweet.

용법과 용량: 1회 7.5g, 1일 2~3회 끓인 물에 타서 복용한다.DOSAGE AND ADMINISTRATION: Take 7.5g once a day and take it in boiled water 2-3 times a day.

실시예Example 8(과립제) 8 (granule)

처방: 중량부에 따라, 실시예 3으로 얻은 물 추출물 1부, 수크로오스 2.5부, 덱스트린 1.5부로 계산한다.Prescription: Calculate with 1 part of the water extract obtained in Example 3, 2.5 parts of sucrose and 1.5 parts of dextrin, depending on the weight part.

제조방법: 추출물 분말을 수크로오스와 덱스트린에 첨가하고 고르게 혼합하여 과립으로 제조한 후, 건조시켜 분리 포장한다.Preparation method: Extract powder is added to sucrose and dextrin and mixed well to prepare granules, which are then dried and separated.

성상: 본 제품은 황갈색의 과립이며, 맛이 약간 달고 쓰다.Appearance: This product is a yellowish brown granule, taste a little sweet.

용법과 용량: 1회 2.5g, 1일 2~3회 끓인 물에 타서 복용한다.DOSAGE AND ADMINISTRATION: Take 2.5g once a day and take 2 ~ 3 times a day in boiled water.

실시예Example 9( 9 ( 캡슐제Capsule ))

처방: 중량부에 따라, 실시예 4로 얻은 알코올 추출물 1부, 전분 2부로 계산한다.Prescription: Calculated by weight part, 1 part of alcohol extract obtained in Example 4 and 2 parts of starch.

제조방법: 추출물 분말을 전분에 첨가하고 고르게 혼합하여 과립으로 제조한 후, 건조시켜 캡슐에 담는다.Preparation method: Extract powder is added to starch and mixed well to form granules, which are dried and encapsulated.

성상: 본 제품은 캡슐제로 내용물은 진한 갈색의 과립 또는 분말이며, 맛은 약간 쓰다.Appearance: This product is capsules, the contents are dark brown granules or powder, taste slightly.

용법과 용량: 1회 3캡슐, 1일 2~3회 구복한다. DOSAGE AND ADMINISTRATION: Take 3 capsules once or twice or three times a day.

실시예Example 10(정제) 10 (tablet)

처방: 중량부에 따라, 실시예 5로 얻은 알코올 추출물 1부, 전분 2부, 스테아르산마그네슘 적량으로 계산한다.Prescription: Calculate the amount of the alcohol extract obtained in Example 5, the starch 2 parts, and the amount of magnesium stearate, based on the weight.

제조방법: 추출물 분말을 전분에 첨가하고 고르게 혼합하여 과립으로 제조한 후, 건조시킨 다음 스테아르산마그네슘을 첨가하여 정제로 제조한다.Preparation method: Extract powder is added to starch and mixed evenly to prepare granules, which are then dried and then purified by adding magnesium stearate.

성상: 본 제품은 진한 갈색의 정제이며, 맛은 약간 쓰다.Appearance: This product is a dark brown tablets, taste a little bit.

용법과 용량: 1회 3정, 1일 2~3회 구복한다. DOSAGE AND ADMINISTRATION: Take 3 tablets once or twice a day.

이하 실험을 통해 본 발명의 약물 작용 원리와 유익한 효과에 대해 좀 더 구체적으로 설명한다:Hereinafter, the drug action principle and beneficial effects of the present invention will be described in more detail by way of experiments:

1. 실험 재료 및 방법1. Materials and Methods

1) 실험 약물: 백자채 물 추출물(1.3g의 생약/ml) 및 알코올 추출물(2.6g의 생약/ml)1) Experimental drug: white water extract (1.3 g of herbal medicine / ml) and alcohol extract (2.6 g of herbal medicine / ml)

비펜데이트(bifendate) 점적환제, 광주 성군(약업) 주식유한공사, 로트번호: JF40021. Bifendate dotted pillow, Gwangju Sungguk (Pharmaceutical) Stock Co., Ltd., Lot No .: JF40021.

2. 동물 NIH 작은 쥐, SPF급, 수컷, 체중 18~22g. 실험동물 품질합격증 번호: 2006A051; SPF급 실험동물 환경조건 합격증 번호: 2006B023; SPF급 실험동물 생산허가증 번호: SCXK 광동 2011-0015; 동물은 남방의과대학 동물실험센터 제공.2. Animals NIH small rat, SPF, male, body weight 18-22g. Laboratory animal quality certificate number: 2006A051; SPF class laboratory animal environmental condition acceptance certificate number: 2006B023; SPF grade laboratory animal production license number: SCXK Guangdong 2011-0015; Animal is provided by Southern Medical University animal experiment center.

3. 주요 화학시약 및 측정장치: 아미노 트랜스페라제(ALT) 측정 키트, 中生北控 생물과기 주식유한공사, 로트번호: 121881; 아스파라긴산 트랜스아미나제(AST) 측정 키트, 中生北控 생물과기 주식유한공사, 로트번호:120921; 사염화탄소 용액, 분석용 시약, 천진시 부녕 정밀화공 유한공사, 로트번호: 111010; 포름알데히드 용액, 분석용 시약, 로트번호 20111007, 광동 광화과기 주식유한공사; 무수에탄올, 분석용 시약, 로트번호 20110416, 천진시 진풍 화공유한공사; 디메틸벤젠, 분석용 시약, 로트번호 20101224, 광동 광화 화학창 유한공사; 헤마톡실린, 생물염색소, 로트번호 060408, 북경 정국 생물기술 유한책임공사 Fluka 수입 포장; 에오신 Y, 생물염색소, 로트번호 20050912, 중국 화동 사범대학 화공창; ECHO LCD 생화학분석기는 이태리 에코사 생산. OLYMPUS AU5421형 전자동 생화학분석기, 일본 OLYMPUS사 생산; OLYMPUS BH-2 형광현미경, 일본 OLYMPUS사 생산; BECKMANTM30형 저온원심분리기, 미국 BACKMAN사 생산; LEICA RM2135형 정제커터기, 독일 LEICA사 생산; SARTORIUS 전자저울, 독일 SARTORIUS사 생산.3. Major Chemical Reagents and Measuring Devices: Aminotransferase (ALT) assay kit, Zhongshan North Biotech Biotechnology Co., Ltd., Lot No: 121881; Aspartic acid transaminase (AST) assay kit, Nakayama North Biotechnology Co., Ltd., Lot number: 120921; Carbon tetrachloride solution, analytical reagent, Tianjin City Boryeong Fine Chemical Co., Ltd., Lot No: 111010; Formaldehyde solution, analytical reagent, lot No. 20111007, Guangdong Guanghua Chemical Co., Ltd.; Anhydrous ethanol, analytical reagent, lot number 20110416, Tianjin City Jinpung Chemical Co., Ltd.; Dimethylbenzene, Analytical Reagent, Lot No 20101224, Guangdong Guanghua Chemical Industry Co., Ltd.; Hematoxylin, biotite, lot No. 060408, Beijing Chungang Biological Technology Co., Ltd. Fluka import packaging; Eosin Y, Biotyping site, Lot No. 20050912, China East China Normal University Chemical window; ECHO LCD Biochemistry Analyzer is produced in Italy. OLYMPUS AU5421 type automatic biochemical analyzer, OLYMPUS production in Japan; OLYMPUS BH-2 fluorescence microscope, OLYMPUS production in Japan; BECKMANTM30 low temperature centrifuge, manufactured by BACKMAN, USA; LEICA RM2135 type tablet cutter, produced by LEICA in Germany; SARTORIUS electronic balance, produced by SARTORIUS Germany.

4. 실험방법 및 용량: 동물을 정상 대조그룹, 모델그룹, 비펜데이트그룹(0.2g/kg), 물 추출 고용량그룹(1.12g/kg), 물 추출 중간용량그룹(0.56g/kg), 물 추출 저용량그룹(0.28g/kg), 알코올 추출 고용량그룹(1.12g/kg), 알코올 추출 중간용량그룹(0.56g/kg), 알코올 추출 저용량그룹(0.28g/kg)으로 분류하였다. 각 그룹당 12마리이며, 연속으로 7일 동안 매일 1회 위장관 투여하였다. 정상대조그룹 및 모델그룹은 동일한 부피의 수돗물을 위장관 투여하였다. 위장관 투여 용적은 0.25ml/10g 작은 쥐이며, 자유롭게 섭식시켰다. 마지막 회 위장관 투여 1시간 후 0.12%(체적비)의 사염화탄소(순 땅콩유로 조제) 0.2ml/마리를 복강 주사하였다. 물을 제외하고 금식시켰으며, 16시간 후 안구를 적출하고 혈액을 채취하여 원심분리로 혈청을 취한 후, 글루타민산 피루빈산 트랜스아미나제(GPT) 및 글루타민산 옥살로초산 트랜스아미나제(GOT)를 검출하였다.The animals were divided into two groups: normal control group, model group, biphenate group (0.2 g / kg), water extract high dose group (1.12 g / kg), water extraction intermediate dose group (0.56 g / (0.28 g / kg), the alcohol extraction high dose group (1.12 g / kg), the alcohol extraction intermediate dose group (0.56 g / kg) and the alcohol extraction low dose group (0.28 g / kg). Twelve rats per group were administered gastrointestinal tract once a day for seven consecutive days. The normal control group and the model group received gastrointestinal administration of the same volume of tap water. The gastrointestinal administration volume was 0.25 ml / 10 g small mice and they were fed freely. One hour after administration of the last gastrointestinal tract, 0.2 ml / volume of 0.12% (by volume) carbon tetrachloride (pure peanut oil) was injected intraperitoneally. After 16 hours, the eyeballs were harvested and blood was collected. The serum was taken by centrifugation, and then glutamate pyruvate transaminase (GPT) and glutamate oxaloacetate transaminase (GOT) were detected Respectively.

5. 병리학 검사: 간장 좌엽을 중성 포르말린으로 고정시키고, 통상적인 방법으로 탈수시켜 절편(4미크론)을 왁스 포매하고, HE 염색하여, 광학현미경으로 간조직의 병리학 변화를 관찰하였다. 간조직 손상 정도를 4급(1)으로 분류하였다: 0급(-), 간 조직 구조 정상, 변성, 괴사 및 염증세포 침윤의 뚜렷하지 않음; Ⅰ급(+), 간 소엽 구조가 아직 정상이고, 일부 간세포가 혼탁하고 부어오른 것을 볼 수 있으며, 풍선 모양의 변형 또는 지방 변성이 있고, 점상 괴사가 산재해 있음; Ⅱ급(++), 간 소엽 구조가 분명하지 않고, 뚜렷한 소상 괴사를 볼 수 있으며, 염증세포 침윤이 수반됨; Ⅲ급(+++), 간 소엽 구조가 분명하지 않고, 뚜렷한 편상 괴사를 볼 수 있으며, 염증세포 침윤이 수반됨.5. Pathological examination: The hepatic lobe was fixed with neutral formalin, dehydrated by conventional method, and the section (4 micron) was wax-embedded, HE stained, and the pathological changes of the liver tissue were observed with an optical microscope. The extent of hepatic tissue damage was classified as grade 4 (1): grade 0 (-), normal liver structure, denaturation, necrosis, and inflammatory cell infiltration not evident; Ⅰ (+), liver lobular structure is still normal, some hepatocytes are seen to be cloudy and swollen, balloon shaped deformation or fat degeneration, dot necrosis scattered; Ⅱ class (++), liver lobular structure is not clear, distinct small necrosis is visible, accompanied by inflammatory cell infiltration; Ⅲ class (+++), liver lobular structure is not clear, distinct necrosis is seen, and inflammatory cell infiltration is accompanied.

6. 실험데이터는

Figure pct00001
및 등급/빈도분포표 자료로 표시하였으며, spss 8.0 통계 소프트웨어 One-Way ANOVA LSD 또는 Dunnett T3법 및 Nonparametric Test 2 Independent Samples Tests법으로 데이터를 처리하였다.6. The experimental data
Figure pct00001
Data were analyzed using SPSS 8.0 statistical software One-Way ANOVA LSD or Dunnett T3 method and Nonparametric Test 2 Independent Samples Tests.

2. 검사 결과:2. Test results:

1) 간 기능 검사 결과1) Liver function test result

작은 쥐의 혈청 글루타민산 피루빈산 트랜스아미나제(GPT), 글루타민산 옥살로초산 트랜스아미나제(GOT) 검사 결과는 표 1을 참조한다.The results of the test for serum glutamic acid pyruvate transaminase (GPT) and glutamate oxaloacetic acid transaminase (GOT) in small rats are shown in Table 1.

그룹별 By group GPT(U/L)GPT (U / L) GOT(U/L)GOT (U / L) 정상그룹
모델그룹
비펜데이트그룹
물 추출 고용량그룹
물 추출 중간용량그룹
물 추출 저용량그룹
알코올 추출 고용량그룹
알코올 추출 중간용량그룹
알코올 추출 저용량그룹
Normal group
Model Group
Biphen Dating Group
Water Extraction High Capacity Group
Water Extraction Medium Capacity Group
Water Extraction Low Capacity Group
Alcohol Extraction High Capacity Group
Alcohol Extraction Intermediate Capacity Group
Alcohol Extraction Low Capacity Group
43±6**
317±112
47±9**
178±63*
193±74
230±81
162±90*
231±75
224±105
43 ± 6 **
317 ± 112
47 ± 9 **
178 ± 63 *
193 ± 74
230 ± 81
162 ± 90 *
231 ± 75
224 ± 105
113±17**
303±96
240±73
135±29*
173±71
262±87
220±31*
238±79*
292±68
113 ± 17 **
303 ± 96
240 ± 73
135 ± 29 *
173 ± 71
262 ± 87
220 ± 31 *
238 ± 79 *
292 ± 68

[각 실험그룹의 작은 쥐의 혈청 GPT, GOT 검사 결과(

Figure pct00002
, N=12)][Serum GPT, GOT results of small mice in each experimental group (
Figure pct00002
, N = 12)]

주: *는 모델그룹과 비교하여, P<0.05; **는 모델그룹과 비교하여, P<0.01.
Note: * compared to the model group, P <0.05; ** compared to the model group, P <0.01.

표 1을 통해, 모델그룹과 정상그룹을 비교해보면, 혈청 글루타민산 피루빈산 트랜스아미나제(GPT) 및 글루타민산 옥살로초산 트랜스아미나제(GOT)가 모두 뚜렷이 상승하였고(P<0.01); 비펜데이트그룹은 혈청 트랜스아미나제가 뚜렷이 하강하였으며(P<0.01); 백자채 물 추출물 및 알코올 추출물 고용량그룹의 혈청 글루타민산 피루빈산 트랜스아미나제(GPT) 및 글루타민산 옥살로초산 트랜스아미나제(GOT)는 모두 뚜렷이 하강하였고(P<0.05); 백자채 알코올 추출물 중간용량그룹의 글루타민산 옥살로초산 트랜스아미나제가 뚜렷이 하강하였음(P<0.05)을 알 수 있다.Table 1 shows that both serum and glutamic acid pyruvate transaminase (GPT) and glutamate oxaloacetate transaminase (GOT) were significantly elevated (P <0.01); In the biphenate group, serum transaminase significantly decreased (P <0.01); Both the serum glutamate pyruvate transaminase (GPT) and the glutamate oxaloacetic acid transaminase (GOT) in the high dose group of white porcelain water extract and alcohol extract were all significantly lowered (P <0.05); (P < 0.05) of the intermediate dose group of glutamate oxaloacetic acid transaminase in white alchohol extracts.

2) 급성 간 손상 작은 쥐의 간 조직 병리학적 손상에 대한 영향2) Effect of acute liver injury on liver histopathologic damage in small rats

병리 절편 결과, 정상대조그룹의 작은 쥐 간 조직 구조는 정상이었고, 간세포가 중앙정맥을 중심으로 방사상으로 배열되어 있으며, 간세포색, 간 동양 모세혈관의 배열이 규칙적이고, 간 소엽 구조가 완전하였으며, 일부 동물의 간세포에서 경도의 부종, 점상괴사 등 병리 변화를 볼 수 있었다. CCL4 모델그룹의 작은쥐는 대다수의 간세포가 고리형으로 중앙정맥에 혼탁한 부종이 분포되었고, 세포질이 팽화되었으며, 풍선 모양의 변형이 보이는 것도 있었다. 간 소엽 중앙정맥과 간피막하에 분포된 간세포는 점상, 소상 또는 편상괴사가 있었고, 염증성 세포 침윤 등 병리 변화가 수반되었다. 비펜데이트그룹 및 백자채 알코올 추출, 물 추출 고용량그룹은 간세포 괴사를 현저히 경감시킬 수 있었으며(P<0.05), 이는 백자채 알코올 추출, 물 추출 고용량그룹이 CCL4 복강주사로 인한 간 손상에 대해 보호 작용이 있음을 나타낸다.As a result, hepatocytes were arranged radially around the central vein, hepatocyte colony, hepatic capillaries were arranged regularly, liver lobular structure was complete, In some animal hepatocytes, pathologic changes such as edema of the hardness and necrosis of the stomach were observed. The small rats of the CCL 4 model group showed that most of the hepatocytes were annular, with turbid edema in the central vein, cytoplasmic swelling, and balloon-shaped deformation. Hepatic cells distributed in the hepatic lobule central vein and hepatic capsule were papillary, pancreatic or necrotic necrosis, accompanied by pathologic changes such as inflammatory cell infiltration. The biphenate group and white liquor extraction and water extraction high dose groups were able to significantly reduce hepatocyte necrosis (P <0.05), indicating that high-dose white sugar alcohols extraction and water extraction groups protect against hepatic damage due to CCL 4 intraperitoneal injection .

표 2: 각 실험그룹 작은 쥐의 CCL4로 인한 급성 간 손상조직에 대한 병리학적 영향Table 2: Pathological effects of acute liver injury tissues due to CCL 4 in each experimental group of small rats

Figure pct00003
Figure pct00003

주: P값은 각 그룹과 모델그룹을 비교한 결과이다.Note: The P value is the result of comparing each group with the model group.

3. 실험 결론:3. Experimental Conclusion:

본 실험을 통해, CCl4로 인한 작은 쥐의 급성 간 손상에 대하여, 백자채 알코올 추출, 물 추출 고용량그룹에 뚜렷하게 억제작용이 있음을 밝혔으며, 혈청 글루타민산 피루빈산 트랜스아미나제(GPT) 및 글루타민산 옥살로초산 트랜스아미나제(GOT)를 하강시켜, 간세포 변성과 괴사를 경감시키는 것으로 나타났다.In this experiment, we found that the inhibitory effect of CCl 4 on the acute liver injury of small rats was significantly inhibited by the extraction of white porcelain alcohol and the high water extract group. In addition, serum glutamate pyruvate transaminase (GPT) and glutamic acid Oxaloacetic acid transaminase (GOT) was lowered to reduce hepatocyte denaturation and necrosis.

Claims (5)

백자채의 간염 치료 약물 또는 건강식품 제조에의 응용에 있어서,
상기 약물 또는 건강식품은 백자체 추출물과 통상적인 용량의 약제학적으로 허용 가능한 보조재를 혼합하여 제조되는 임상적으로 허용 가능한 제제인 것을 특징으로 하는 백자채의 간염 치료 약물 또는 건강식품 제조에의 응용.
In the treatment of hepatitis in white porcelain,
Wherein the medicament or the health food is a clinically acceptable preparation which is prepared by mixing a white tea extract with a conventional dose of a pharmaceutically acceptable auxiliary material.
제 1항에 있어서,
상기 백자채 추출물은 물 추출물 또는 알코올 추출물인 것을 특징으로 하는 백자채의 간염 치료 약물 또는 건강식품 제조에의 응용.
The method according to claim 1,
Wherein the white raspberry extract is a water extract or an alcohol extract, and wherein the white raspberry extract is a water extract or an alcohol extract.
제 2항에 있어서,
상기 물 추출물의 제조방법은, 백자채에 8~12배의 물을 첨가하고, 1.5~2시간동안 달인 후, 찌꺼기에 다시 5~8배량의 물을 첨가하여 1~1.5시간 동안 달여 추출액을 합병한 후 여과 농축시키는 단계를 포함하는 것을 특징으로 하는 백자채의 간염 치료 약물 또는 건강식품 제조에의 응용.
3. The method of claim 2,
The water extract is prepared by adding 8 to 12 times of water to white porcelain, agitating for 1.5 to 2 hours, adding 5 to 8 times of water to the residue, adding the extract for 1 to 1.5 hours, And then filtering and concentrating the resulting product.
제 2항에 있어서,
상기 알코올 추출물의 제조방법은 백자채에 8~12배의 75%~90% 에탄올을 첨가하고, 1.5~2시간 동안 환류 추출한 후, 찌꺼기에 75%~90%배량의 물을 다시 첨가하여 1~1.5시간 동안 달여 추출액을 합병한 후 여과하고, 에탄올을 회수하여 농축시키는 단계를 포함하는 것을 특징으로 하는 백자채의 간염 치료 약물 또는 건강식품 제조에의 응용.
3. The method of claim 2,
The alcohol extract is prepared by adding 75 to 90% ethanol of 8-12 times to white flour, refluxing for 1.5-2 hours, adding 75% ~ 90% of water to the residue, Which comprises collecting the extracts for a period of 1.5 hours, filtering the extracts, and recovering and concentrating the ethanol.
제 1항에 있어서,
상기 제제는 임상적으로 허용 가능한 과립제, 캡슐제, 정제 또는 구복액인 것을 특징으로 하는 백자채의 간염 치료 약물 또는 건강식품 제조에의 응용.
The method according to claim 1,
Wherein the preparation is a clinically acceptable granule, capsule, tablet or fabric solution.
KR1020157003623A 2013-05-15 2014-04-28 Application of gynura divaricata in preparing medicine or health food for treating hepatitis KR20150036538A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310179552.9 2013-05-15
CN201310179552.9A CN103222995B (en) 2013-05-15 2013-05-15 Application of gynura divaricata in preparing liver-protecting drug or health-care food
PCT/CN2014/076376 WO2014183551A1 (en) 2013-05-15 2014-04-28 Application of gynura divaricata in preparing medicine or health food for treating hepatitis

Publications (1)

Publication Number Publication Date
KR20150036538A true KR20150036538A (en) 2015-04-07

Family

ID=48833791

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157003623A KR20150036538A (en) 2013-05-15 2014-04-28 Application of gynura divaricata in preparing medicine or health food for treating hepatitis

Country Status (7)

Country Link
JP (1) JP2015524813A (en)
KR (1) KR20150036538A (en)
CN (1) CN103222995B (en)
GB (1) GB2522146B (en)
HK (1) HK1212589A1 (en)
SG (1) SG11201501648SA (en)
WO (1) WO2014183551A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103222995B (en) * 2013-05-15 2014-09-03 李伟权 Application of gynura divaricata in preparing liver-protecting drug or health-care food
CN103230444B (en) * 2013-05-15 2014-03-19 李伟权 Traditional Chinese medicine composition for lowering lipid and protecting liver as well as preparation method and application thereof
CN110368411B (en) * 2019-08-02 2021-08-06 龙岩学院 Extraction process and separation and purification method of gynura bicolor polyphenol
CN112655601A (en) * 2020-12-02 2021-04-16 中国水产科学研究院淡水渔业研究中心 Establishment and application of model for inducing freshwater fish acute liver and intestine combined injury by carbon tetrachloride

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10251154A (en) * 1997-03-13 1998-09-22 Suntory Ltd Composition for inhibiting hepatitis
EP1718167A4 (en) * 2004-01-31 2010-07-14 Kiyoung Kim Composition comprising hovenia dulcis thunb. extract, lindera obtusiloba blume extract, or herbal mixture extract thereof
JP2008074807A (en) * 2006-09-25 2008-04-03 Oriza Yuka Kk Hepatoprotector
CN101485706A (en) * 2008-01-19 2009-07-22 郑乐建 Gynura divaricata (L.) DC. with oxidation-resisting, free radical-resisting and face plaque-removing functions and soft capsule preparation thereof
JP5422200B2 (en) * 2008-12-26 2014-02-19 株式会社ヤクルト本社 Liver dysfunction improving agent
CN102631391A (en) * 2012-05-15 2012-08-15 李伟权 Application of gynura divaricata in preparing lipid-lowering medicine or health-care food
CN103222995B (en) * 2013-05-15 2014-09-03 李伟权 Application of gynura divaricata in preparing liver-protecting drug or health-care food

Also Published As

Publication number Publication date
CN103222995B (en) 2014-09-03
GB201507323D0 (en) 2015-06-10
HK1212589A1 (en) 2016-06-17
GB2522146A (en) 2015-07-15
CN103222995A (en) 2013-07-31
WO2014183551A1 (en) 2014-11-20
SG11201501648SA (en) 2016-01-28
JP2015524813A (en) 2015-08-27
GB2522146B (en) 2016-02-10

Similar Documents

Publication Publication Date Title
KR100795822B1 (en) Natural plant extract composition for prevention and recovery of hyperlipidemia and stroke, natural tee including the same as effective components and the preparation method thereof
KR101751398B1 (en) Composition comprising Angelica gigas Nakai, Cornus officinalis, Cervi Parvum Cornu, Red ginseng, Rehmanniae Radix Preparata, Aquilaria agallocha Roxburgh and Honey for anti-inflammation
KR101817055B1 (en) Food composition having anti-obesity, anti-cancer, anti-oxidative and immunity enhancing activities
JP2022545288A (en) Tea composition for prevention, improvement or effect of respiratory disease and pharmaceutical composition containing the same
KR20150036538A (en) Application of gynura divaricata in preparing medicine or health food for treating hepatitis
KR101710303B1 (en) Pharmaceutical composition containing elaeagnus umbellata thunberg extract for immune-enhancing
KR101794006B1 (en) Anti inflammatory comprising plant extract
KR20200084212A (en) Anti-obesity composition comprising extract of Sargassum horneri
KR20140034620A (en) Composition for preventing or treating diabetbes mellitus disease containing extract of plants
KR101517833B1 (en) A composotion for the treatment of dyslipidemia comprising the red ginseng complex
KR101692032B1 (en) Anti-cancer composition containing erythronium japonicum extract
CN105901738A (en) Fermentation grape extract, preparing method of fermentation grape extract and preparation containing fermentation grape extract
KR101919161B1 (en) Composition for improving condition of hair and preventing hair loss
KR101768612B1 (en) Food composition for improving liver function and method of health tea using thereof
KR101028073B1 (en) Natural herb medicine composition improving blood circulation and immune activity of human body and its process of production
CN104758309A (en) Application of strawberry polysaccharide in reduction of blood sugar
KR20190062833A (en) Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata
KR101615923B1 (en) Composition Comprising Extracts of Boehmeria tricuspis, Angelica decursiva or Arctium lappa Having Anti-allergy or Anti-inflammation
KR102604905B1 (en) Composition for immune enhancing comprising sprout Angelica gigas extract
KR20190119020A (en) A composition for anti-inflammation comprising hemistepta lyrata extract
CN104940428B (en) Hypoglycemic composition containing wolfberry fruits and application thereof
KR102546935B1 (en) A composition for preventing or improving diabetes containing a radish extract as an active ingredient and a method for producing the same
KR102617383B1 (en) Anti-obesity composition using pomegranate, dioscorea rhizoma and polygonatum odratum extract as effective component and manufacturing method thereof
KR102496864B1 (en) Anti-obesity composition containing extract of Paliurus ramosissimus as an active ingredient
JP7385013B2 (en) Composition for improving stamina and natural tea for improving stamina containing the same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application